KR900700099A - 국소투여 메트로니다졸 제형 및 이의 치료학적 용도 - Google Patents

국소투여 메트로니다졸 제형 및 이의 치료학적 용도

Info

Publication number
KR900700099A
KR900700099A KR1019890701701A KR890701701A KR900700099A KR 900700099 A KR900700099 A KR 900700099A KR 1019890701701 A KR1019890701701 A KR 1019890701701A KR 890701701 A KR890701701 A KR 890701701A KR 900700099 A KR900700099 A KR 900700099A
Authority
KR
South Korea
Prior art keywords
formulation
composition
weight
total weight
present
Prior art date
Application number
KR1019890701701A
Other languages
English (en)
Other versions
KR0135313B1 (ko
Inventor
제이. 보그만 로버트
Original Assignee
원본 미기재
쿠라텍 파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본 미기재, 쿠라텍 파마슈티칼스, 인코포레이티드 filed Critical 원본 미기재
Publication of KR900700099A publication Critical patent/KR900700099A/ko
Application granted granted Critical
Publication of KR0135313B1 publication Critical patent/KR0135313B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

국소투여 메트로니다졸 제형 및 이의 치료학적 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 겔 조성물(0.75중량% 메트로니다졸 프로필렌 글리콜 함유:pH 약 5.8)로부터 60분동안에 걸친 메트로니다졸의 시험관내 방출을 설명하는 그래프이다. 시험1에 대한 데이타 점은 (0)로 나타내며, 시험 2에 대해서는 (0) 및 시험 3에 대해서는 (X)로 나타내고; 제2도는 제1도에서 설명한 3개의 시험에 대한 메트로니다졸의 평균 방출을 설명하는 그래프이고, 제3도는 기타 겔 조성물(0.75중량% 메트로니다졸;프로필렌글리콜을 함유하지 않음: pH 약 5.8)로부터 60분 동안에 걸친 메트로니다졸의 시험관내 방출을 설명하는 그래프이다. 시험 1에 대한 데이타점은 (0)로 나타내며,시험 2에 대해서는 (0)및 시험 3에 대해서는 (X)로 나타낸다.

Claims (20)

  1. 치료적 유효량의 메트로니다졸, 유리카복실 그룹을 갖는, 겔화된 친수성 수분산성 중합체 및 메트로니다졸용 수성 용매를 포함하는 수성 겔 조성물 형태의 국소 투여용 피부학 제제.
  2. 제1항에 있어서, 메트로니다졸의 농도가 조성물의 총중량을 기준으로 하여 적어도 약 0.1중량%인 제제.
  3. 제2항에 있어서, 존재하는 메트로니다졸의 농도가 조성물의 총 중량을 기준으로 하여 약 0.25내지 약 1.0중량%의 범위내인 제제.
  4. 제3항에 있어서, 존재하는 메트로니다졸의 농도가 조성물의 총 중량을 기준으로 하여 약 0.75중량%인 제제.
  5. 제1항에 있어서, 중합체가 친수성, 수분산성 폴리카복실화 비닐 중합체의 제제.
  6. 제5항에 있어서, 비닐 중합체가 분자량의 범위가 약 1,250,000 내지 약 4,000,000달톤인 폴리아크릴산 중합체인 제제.
  7. 제1항에 있어서, 중합체가 조성물의 총 중량을 기준으로 하여 약 0.2내지 약 7.0중량%의 범위로 존재하는 제제.
  8. 제7항에 있어서, 중합체가 조성물의 총 중량을 기준으로 하여 약 0.5내지 약 1.5중량%의 범위로 존재하는 제제.
  9. 제8항에 있어서, 중합체가 조성물의 총 중량을 기준으로하여 약 0.6중량%의 양으로 존재하는 제제.
  10. 제1항에 있어서, 추가로 투과 증강제를 포함하는 제제.
  11. 제10항에 있어서, 투과 증강제가 조성물의 총 중량을 기준으로 하여 약 2중량%내지 약 5중량%의 범위로 존재하는 프로필렌 글리콜인 제제.
  12. 제11항에 있어서, 투과 증강제가 조성물의 총 중량을 기준으로 하여 약 3중량%의 양으로 존재하는 제제.
  13. 제1항에 있어서, 추가로 방부제를 포함하는 제제.
  14. 제13항에 있어서, 방부제가 적어도 한개의 파라벤을 포함하는 제제.
  15. 제14항에 있어서, 방부제가 조성물의 총 중량을 기준으로하여 약 0.08중량%의 양으로 존재하는 메틸 파라벤 및 약 0.02중량%의 양으로 존재하는 프로필 파라벤인 제제.
  16. 제1항에 있어서, 조성물의 총 중량을 기준으로 하여 약 0.01중량% 내지 약 0.1중량% 범위의 에틸렌디아민테트라 아세트산을 추가로 포함하는 제제.
  17. 치료적 유효량의 메트로니다졸, 유리 카복실 그룹을 갖는 겔형 친수성 수분산성 중합체 및 메트로니다졸의 수성용매를 질환이 있는 피부에 국소적으로 적용시킴을 포함함을 특징으로 하여 피부질환으로 고통받는 사람을 치료하는 방법.
  18. 제17항에 있어서, 피부질환이 주사인 방법.
  19. 제17항에 있어서, 피부질환이 심상성 좌창인 방법.
  20. 제17항에 있어서, 피부질환이 스테로이드성 여드름, 말의 전염성 좌창, 소결절낭포성 여드름, 입주위 피부염 및 지루성 비염을 포함하는 그룹중의 하나인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890701701A 1988-01-15 1989-01-12 국소투여용 메트로니다졸 제형 KR0135313B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US144,252 1988-01-15
US07/144,252 US4837378A (en) 1986-01-15 1988-01-15 Topical metronidazole formulations and therapeutic uses thereof
PCT/US1989/000116 WO1989006537A1 (en) 1988-01-15 1989-01-12 Topical metronidazole formulations and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
KR900700099A true KR900700099A (ko) 1990-08-11
KR0135313B1 KR0135313B1 (ko) 1998-04-23

Family

ID=22507764

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890701701A KR0135313B1 (ko) 1988-01-15 1989-01-12 국소투여용 메트로니다졸 제형

Country Status (11)

Country Link
US (1) US4837378A (ko)
EP (1) EP0355152B1 (ko)
JP (1) JP2714464B2 (ko)
KR (1) KR0135313B1 (ko)
CN (1) CN1032900C (ko)
AT (1) ATE103813T1 (ko)
AU (1) AU621589B2 (ko)
CA (1) CA1297029C (ko)
DE (1) DE68914365T2 (ko)
WO (1) WO1989006537A1 (ko)
ZA (1) ZA89233B (ko)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536743A (en) * 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5614545A (en) * 1988-06-09 1997-03-25 Leonard Bloom Topical composition for treatment of blepharitis
CA1337279C (en) * 1989-06-06 1995-10-10 Robert J. Borgman Intravaginal treatment of vaginal infections with buffered metronidazole compositions
ES2084174T3 (es) * 1990-07-20 1996-05-01 Tillotts Pharma Ag Productos y procesos para el tratamiento del conducto alimentario.
JP3170277B2 (ja) * 1990-08-16 2001-05-28 マーチン，ネイル・エフ 眼瞼炎の局所治療
GB9114346D0 (en) * 1991-07-03 1991-08-21 Dow Corning Sa A method of accelerating drug permeation
US5505948A (en) * 1993-06-01 1996-04-09 Dermatology Home Products, Inc. Home skin peel composition for producing healthy and attractive skin
US5592949A (en) * 1994-06-29 1997-01-14 Moench; Thomas R. Device for acidic buffering and method for inactivation of pathogens
FR2722098B1 (fr) * 1994-07-06 1996-08-23 Cird Galderma Nouveaux medicaments a base de metro-nidazole ou d'un melange synergetique de metronidazole et de clindamycine
WO1997047300A1 (en) * 1996-06-14 1997-12-18 Stiefel Laboratories, Inc. Antimycotics with metronidazole for treatment of skin disorders
IT1284874B1 (it) 1996-08-02 1998-05-22 Farmigea Spa Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici
WO1999004829A1 (en) * 1997-07-28 1999-02-04 Redmond Mary L Composition and process for the treatment of epidermal traumas such as decubitus ulcers
US6502520B1 (en) 1998-01-30 2003-01-07 Hitachi, Ltd. Solid material melting apparatus
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
US6150381A (en) 1998-06-09 2000-11-21 R.J. Reynolds Tobacco Company Methods of treating microbial infection and therapeutic formulations therefor
US6800291B1 (en) * 1999-03-24 2004-10-05 Zengen, Inc. Uro-genital condition treatment system
US7402559B2 (en) * 1999-03-24 2008-07-22 Msh Pharma, Incorporated Composition and method of treatment for urogenital conditions
EP1206937B1 (en) * 1999-07-16 2008-01-23 Shoei Co., Ltd. Nitroimidazole external preparations for the treatment of atopic dermatitis
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US6468989B1 (en) * 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
WO2002094179A2 (en) * 2001-05-23 2002-11-28 J.B. Chemicals & Pharmaceuticals Ltd. Novel topical microbicidal compositions
US6881726B2 (en) * 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9668972B2 (en) * 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
AU2003279493B2 (en) 2002-10-25 2009-08-20 Foamix Pharmaceuticals Ltd. Cosmetic and pharmaceutical foam
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US20050186142A1 (en) * 2002-10-25 2005-08-25 Foamix Ltd. Kit and composition of imidazole with enhanced bioavailability
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8119150B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US10117812B2 (en) * 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
DK1633374T3 (da) * 2003-06-10 2007-12-03 Intendis Gmbh Sammensætning af alkandicarboxylsyrer og et farmaceutisk aktivt stof
FR2856300A1 (fr) * 2003-06-18 2004-12-24 Galderma Res & Dev Composition pharmaceutique topique teinte a base de metronidazole
CA2524739A1 (en) * 2003-06-18 2004-12-29 Galderma S.A. Metronidazole-based green tinted topical pharmaceutical composition
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
WO2005018556A2 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Hydroxylamine substituted imidazo-containing compounds
ES2406730T3 (es) 2003-08-27 2013-06-07 3M Innovative Properties Company Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi
AU2004270201A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US7205006B2 (en) 2003-09-25 2007-04-17 Prime Pharmaceutical Corporation Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
US7456207B2 (en) * 2003-09-25 2008-11-25 Teva Pharmaceuticals Usa, Inc. Vaginal pharmaceutical compositions and methods for preparing them
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
CA2540541C (en) 2003-10-03 2012-03-27 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
EP1685129A4 (en) 2003-11-14 2008-10-22 3M Innovative Properties Co OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
WO2005048945A2 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
JP4891088B2 (ja) 2003-11-25 2012-03-07 スリーエム イノベイティブ プロパティズ カンパニー 置換されたイミダゾ環系および方法
JP2007517035A (ja) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
CA2551399A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
ES2238924B1 (es) 2004-02-17 2006-12-01 Investread Europa, S.L. Uso del acido 2,5-dihidroxibencenosulfonico, en la fabricacion de medicamentos de aplicacion en el tratamiento de enfermedades angiodependientes.
US20080125485A1 (en) 2004-02-17 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
US20070149618A1 (en) 2004-02-17 2007-06-28 Action Medicines, S.L. Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
FR2866570B1 (fr) * 2004-02-20 2007-08-24 Galderma Res & Dev Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter une inflammation cutanee
FR2866568B1 (fr) * 2004-02-20 2007-08-24 Galderma Res & Dev Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter un desordre de la vascularisation cutanee
FR2866569B1 (fr) * 2004-02-20 2007-08-24 Galderma Res & Dev Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter des pathologies liees au recepteur de type b de l'interleukine 8 et/ou au recepteur de type 1 de pacap
CA2559863A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
FR2887149B1 (fr) 2005-06-17 2007-08-03 Galderma Sa Procede de solubilisation du metronidazole
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US20060034779A1 (en) * 2004-08-02 2006-02-16 Agis Industries (1983) Ltd. Foamable compositions containing vitamin D3 analogues, processes for preparing same and methods of treatment utilizng same
US20060024243A1 (en) * 2004-08-02 2006-02-02 Agis Industries (1983) Ltd. Foamable compositions containing nitro-imidazoles, processes for preparing same and methods of treatment utilizing same
US20060057075A1 (en) * 2004-08-02 2006-03-16 Moshe Arkin Pharmaceutical and cosmeceutical wash-off mousse shampoo compositions, processes for preparing the same and uses thereof
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
AU2005322898B2 (en) 2004-12-30 2011-11-24 3M Innovative Properties Company Chiral fused (1,2)imidazo(4,5-c) ring compounds
CA2597092A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
FR2882552B1 (fr) * 2005-02-25 2008-12-26 Galderma Sa Gel aqueux de haute stabilite a base de metronidazole et procedes pour leur preparation
CA2602590A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
JP2008540508A (ja) 2005-05-09 2008-11-20 フォーミックス エルティーディー． 起泡性ビヒクル及びその医薬組成物
WO2006138056A1 (en) * 2005-06-15 2006-12-28 Apollo Pharmaceutical, Inc. Pharmaceutical composition comprising a mahonia aquifolium extract for the treatment of psoriasis
WO2007002447A2 (en) * 2005-06-23 2007-01-04 Bioform Medical, Inc. Compositions for treating rosacea
FR2889662B1 (fr) * 2005-08-11 2011-01-14 Galderma Res & Dev Emulsion de type huile-dans-eau pour application topique en dermatologie
FR2890560B1 (fr) * 2005-09-13 2011-06-24 Galderma Sa Mousses dermatologiques a base de metronidazole et emulsions pour leur preparation
FR2890559B1 (fr) * 2005-09-13 2011-06-24 Galderma Sa Mousses dermatologiques a base de metronidazole et emulsions pour la preparation
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
US20080113948A1 (en) 2006-08-16 2008-05-15 Action Medicines Use of 2,5-Dihydroxybenzene Compounds and Derivatives for the Treatment of Psoriasis
WO2008020025A1 (en) 2006-08-16 2008-02-21 Action Medicines, S.L. Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis
US8258164B2 (en) * 2006-09-12 2012-09-04 Curatek Pharmaceuticals Holding, Inc. Nitroimidazole composition and method
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009090558A2 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US20100105750A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
CN102686205A (zh) 2009-10-02 2012-09-19 弗艾米克斯有限公司 局部四环素组合物
US8174881B2 (en) 2009-11-24 2012-05-08 Micron Technology, Inc. Techniques for reducing disturbance in a semiconductor device
CN107823123A (zh) 2011-06-28 2018-03-23 化学研究有限公司 高剂量粘膜粘附甲硝唑水基凝胶制剂及其治疗细菌性阴道病的用途
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) * 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
CA2916002A1 (en) 2013-06-25 2014-12-31 Mission Pharmacal Company Novel formulations for the treatment of vaginal disorders
EP3452105B1 (en) * 2016-05-06 2021-07-28 Albany Medical College Treatment of rosacea with erk kinase pathway inhibitors
MX2017011630A (es) 2016-09-08 2018-09-25 Foamix Pharmaceuticals Ltd Composiciones y metodos para tratar rosacea y acne.
US11529346B2 (en) * 2020-06-18 2022-12-20 National Medical Supply, LLC Vaginal gel
WO2022269665A1 (ja) * 2021-06-21 2022-12-29 マルホ株式会社 外用剤
CN113476397B (zh) * 2021-07-12 2022-11-18 海南海神同洲制药有限公司 一种甲硝唑凝胶及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2944061A (en) * 1957-09-20 1960-07-05 Acyl derivatives and process
US3883661A (en) * 1971-11-09 1975-05-13 Syntex Inc Acne treatment
JPS56161323A (en) * 1980-05-14 1981-12-11 Hisamitsu Pharmaceut Co Inc Anti-inflammatory and pain-killing gel
US4491588A (en) * 1982-03-31 1985-01-01 University Of Tennessee Research Corporation Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics
JPS5970613A (ja) * 1982-10-14 1984-04-21 Kiyuushin Seiyaku Kk 抗真菌軟膏剤
DE3244027A1 (de) * 1982-11-27 1984-05-30 Bayer Ag, 5090 Leverkusen Antimykotische mittel mit hoher wirkstoff-freisetzung in form von gelsystemen
JPS6136219A (ja) * 1984-07-27 1986-02-20 Shiseido Co Ltd 皮膚外用剤
DE3340872A1 (de) * 1983-11-11 1985-05-23 Theodor Prof Dr Eckert Herstellung von resorptionsfoerdernden waessrigen salbengelen aus polyacrylsaeure oder methacrylsaeure-mischpolymerisaten unter verwendung von harnstoff als gelbildner
GB8607159D0 (en) * 1986-03-22 1986-04-30 Smith & Nephew Ass Pharmaceutical composition
EP0305380B1 (en) * 1987-03-20 1991-09-25 Galderma S.A. Novel topical metronidazole formulations
US5013545A (en) * 1987-12-09 1991-05-07 Thames Pharmacal Co., Inc. Aqueous gels containing topical medicaments

Also Published As

Publication number Publication date
EP0355152A4 (en) 1990-06-27
AU3043289A (en) 1989-08-11
EP0355152B1 (en) 1994-04-06
WO1989006537A1 (en) 1989-07-27
AU621589B2 (en) 1992-03-19
JPH02503004A (ja) 1990-09-20
DE68914365T2 (de) 1994-08-11
ZA89233B (en) 1990-09-26
CN1032900C (zh) 1996-10-02
JP2714464B2 (ja) 1998-02-16
US4837378A (en) 1989-06-06
CA1297029C (en) 1992-03-10
KR0135313B1 (ko) 1998-04-23
EP0355152A1 (en) 1990-02-28
CN1035435A (zh) 1989-09-13
DE68914365D1 (de) 1994-05-11
ATE103813T1 (de) 1994-04-15

Similar Documents

Publication Publication Date Title
KR900700099A (ko) 국소투여 메트로니다졸 제형 및 이의 치료학적 용도
JP4139860B2 (ja) 浸透増強および刺激減少システム
US4500511A (en) Antiinflammatory and analgesic gel
DE69226491T2 (de) Verbesserung der Durchdringungfähigkeit von topischen Anwendbaren Formulierungen
US4775529A (en) Steroid lotion
KR910014117A (ko) 하이드로알콜성 겔을 사용한 이부프로펜의 경피전달 방법
JPH01110619A (ja) 粘膜および義歯接着性ペーストの基剤およびその製法
BR0307550B1 (pt) composição farmacêutica em gel tópica, de adapaleno 0,3%
DK1073439T3 (da) Farmaceutisk sammensætning
KR890701113A (ko) 신규한 국소용 메트로니다졸 제제 및 이의 치료학적 용도
US4244948A (en) Medical use of esters of acetylsalicylic acid to treat acne
IE831611L (en) Topical anti-inflammatory compositions
PT93638A (pt) Processo para a preparacao de uma composicao para a aplicacao topica do acido da vitamina a
MXPA02008518A (es) Extracto de echinacea como anti- irritante y reforzador anti-envejecimiento en composiciones cosmeticas.
Lowe et al. Anthralin for psoriasis: short-contact anthralin therapy compared with topical steroid and conventional anthralin
RU2181285C2 (ru) Гелевая система нимесулида для местного применения и способ ее получения (варианты)
US5098717A (en) Method of treatment for pruritus
MONASH Topical anesthesia of the unbroken skin
US4923875A (en) Method for treatment of mast cell-mediated dermatologic disorders
JPH0231052B2 (ko)
US20080027026A1 (en) Composition for the treatment of inflammatory conditions
ATE29214T1 (de) Topische antiinflammatorische mittel.
CA2135687A1 (en) Method for the treatment and/or prevention of radiation burn

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20111221

Year of fee payment: 15

EXPY Expiration of term